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Myocardial infarct requires prompt thrombolytic therapy or primary percutaneous
coronary intervention to limit the extent of necrosis, but reperfusion creates additional
damage. Along with reperfusion, a maladaptive remodeling phase might occur and it
is often associated with inflammation, oxidative stress, as well as a reduced ability
to recover metabolism homeostasis. Infarcted individuals can exhibit reduced lipid
turnover and their accumulation in cardiomyocytes, which is linked to a deregulation of
peroxisome proliferator activated receptors (PPARs), controlling fatty acids metabolism,
energy production, and the anti-inflammatory response. We previously demonstrated
that Myriocin can be effectively used as post-conditioning therapeutic to limit
ischemia/reperfusion-induced inflammation, oxidative stress, and infarct size, in a
murine model. In this follow-up study, we demonstrate that Myriocin has a critical
regulatory role in cardiac remodeling and energy production, by up-regulating the
transcriptional factor EB, PPARs nuclear receptors and genes involved in fatty acids
metabolism, such as VLDL receptor, Fatp1, CD36, Fabp3, Cpts, and mitochondrial
FA dehydrogenases. The overall effects are represented by an increased β–oxidation,
together with an improved electron transport chain and energy production. The potent
immunomodulatory and metabolism regulatory effects of Myriocin elicit the molecule
as a promising pharmacological tool for post-conditioning therapy of myocardial
ischemia/reperfusion injury.
Keywords: sphingolipids, ceramide, myriocin, ischemia, reperfusion, metabolism
Abbreviations: ETC, electron transfer chain; FA, fatty acids; FAO, fatty acids oxidation; LAD, left anterior descending; Myr,
Myriocin; SLN, solid lipid nanoparticles.
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INTRODUCTION
Myocardium infarct and heart failure are leading causes
of morbidity and mortality in developed countries. When
ischemia occurs, immediate thrombolytic therapy or primary
percutaneous coronary intervention is required to limit the
extent of necrosis (Frank et al., 2012). On the other hand,
inevitably, reperfusion induces additive injury, estimated to
contribute up to 50% of the infarct lesion, ultimately causing
functional impairment and arrhythmia in the post-infarct phase,
when damages extend to ventricular dilation, mitral valve
regurgitation, loss of contractile force, ionic unbalance, and
biochemical, neuroendocrine, and energy metabolism changes.
Such a vicious cycle, named “cardiac remodeling,” afflicts
approximately 30% of infarcted patients (Picard et al., 1990;
Flachskampf et al., 2011; Konstam et al., 2011; Frank et al.,
2012; Curley et al., 2018). In the normal heart, fatty acid
(FA) and glucose metabolism are both required and tightly
regulated, although nearly 70% of cardiac ATP derives from
FA oxidation (Park and Goldberg, 2012). Upon ischemia, the
myocardium immediately shuts off oxygen-consuming processes,
and it temporarily relies on anaerobic glycolysis. This process,
while sparing oxygen, results in poor levels of ATP and
reduces cell pH because of lactate accumulation. Once blood
flow is restored, mitochondrial oxidative phosphorylation is
recovered, and aerobic glycolysis and FA oxidation activity are
restored. In this recovery phase, depending on the severity
of the ischemia/reperfusion (I/R) injury, the overall oxidative
metabolism may be depressed, thus reducing energy fueling
and contributing to maladaptive myocardial remodeling, which
leads to hypertrophy and heart failure. In this latter condition,
the myocardium switches to a fetal-like profile that includes
down-regulation of myosin heavy chain (MHC) -α and up-
regulation of its fetal isoform β (Lowes et al., 1997), associated
with contractile dysfunction, low lipid/high glucose metabolic
consumption, poor ATP production (Qanud et al., 2008;
Karwi et al., 2018) and lipid overload (Schulze et al., 2016).
Any given post-conditioning therapy is aimed at limiting
I/R additive damages. Unfortunately, anti-inflammatory post-
conditioning therapies failed in human trials, indicating that a
regulated inflammatory response and its resolution are necessary
for functional tissue recovery in the post-infarction phase
(Huang and Frangogiannis, 2018).
Recently, a pathological role of lipids metabolism deregulation
had been proposed in tissue remodeling. Cardiac adipose
tissue surrounds the heart (epicardial and pericardial fat),
providing mechanical support. Moreover, myocardium buffers
the excess of circulating free FA by metabolic consumption,
contributing to total body lipid homeostasis (Antonopoulos
and Antoniades, 2017). Advanced morphological and functional
assessment enabled the identification of metabolic changes in
lipid metabolism in the infarcted myocardium (Wong et al.,
2017). Infarcted individuals exhibit an accumulation of fat
in the left ventricle that reaches up to 60% throughout
the ventricle (from 20% of the basal area only in healthy
myocardium) (Pouliopoulos et al., 2013; Sasaki et al., 2015).
Increased intra-myocardial fat was related to altered electrical
activity (Iozzo, 2011; Chhabra and Gurukripa Kowlgi, 2015;
Samanta et al., 2016; Wong et al., 2017) and a direct association
was demonstrated between myocardial dysfunction (Schulze,
2009) and fat replacement of fibrous tissue within ischemia-
produced scar (Pouliopoulos et al., 2013; Sasaki et al., 2015).
Reduced lipid turnover and accumulation is associated with
altered expression and function of peroxisome proliferator
activated receptors (PPARs) family of nuclear receptors,
regulating FAs metabolism, energy production and anti-
inflammatory response (Ravingerova et al., 2011). The three
isoforms, PPAR-α, PPAR-β/δ and PPAR-γ are all expressed in
the myocardium, although to a different extent, and the α and
β/δ subtypes are down-regulated in pathological myocardial
inflammation, fetal metabolic profile switch and hypertrophy
(Liang et al., 2003; Smeets et al., 2008a,b). Activation of PPAR-
γ in infarcted myocardium improved contractile recovery
and/or reduced infarct size after ischemia and reperfusion
(Yue et al., 2005; Geng et al., 2006; Cao et al., 2007; Liu
et al., 2009; Yasuda et al., 2009). Interestingly, PPAR-α and
PPAR-γ synthetic agonists are in use as hypolipidemic and
antidiabetic drugs and have been reported to protect the
heart against ischemia/reperfusion injury (Ravingerova et al.,
2011). Ectopic lipid accumulation in the myocardium, and
in other tissues, harbors lipid droplets formation, a marker
of lipid overload, whose role is to store and coordinate lipid
intracellular transfer use and oxidation, by the action of
specialized proteins such as lipases and perilipins (Goldberg
et al., 2018). Lipid droplets accumulation in cardiac left ventricle
can be envisaged in fasting (Trent et al., 2014) or hypoxia
(Mazzali et al., 2015). Different species are known to give rise
to lipids accrual, with either structural, energetic or signaling
roles. Triacylglycerol, cholesterol and retinyl ester lipids,
ether lipids as well as lipotoxins, such as free cholesterols,
diacylglycerols, and ceramides, are found associated with lipid
droplets (Goldberg et al., 2018).
Ceramide, a sphingoid base containing molecule, is an
important intermediate forming the membrane components
sphingomyelins and glycosphingolipids. Its synthesis, initiated
by serine palmitoyl transferase (SPT), is tightly regulated with
the synthesis rate of other lipids such as cholesterol and
phosphatidylcholine (Ghidoni et al., 2015). Moreover, ceramide
cellular content increases significantly upon stress, affecting cell
cycle, inflammation, and survival. Ceramide accumulation is also
related to reduced PPARs activity (Gao et al., 2015). Ceramide
increase and signaling is a pathological hallmark in a variety
of diseases, and it is a clinically recognized target in cancer,
neurodegenerative, inflammatory and cardiovascular diseases
therapies (Maceyka and Spiegel, 2014; Di Pardo and Maglione,
2018; He and Schuchman, 2018).
Myriocin, which is a specific inhibitor of SPT and of
ceramide de novo synthesis, has been extensively used in vitro
and in vivo in several animal models (Campisi et al., 2017).
Myriocin was demonstrated to reduce myocardial ceramide and
its related insulin resistance (Ussher et al., 2012; Hodson et al.,
2015), as well as oxidative stress (Tippetts et al., 2014; Nelson
et al., 2015). Myriocin reduced cardiac dilation and improved
contractile function in a murine model of cardiomyopathy
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(Park et al., 2008). We recently demonstrated that Myriocin post-
conditioning by intra-ventricular injection of Myriocin-loaded
nanoparticles significantly reduces I/R lesion and inflammation
in the first hours after reperfusion (Reforgiato et al., 2016)
(patent number: US 9925160 B1). Moreover, it has been shown
that dietary administration of Myriocin in the post-infarction
phase ameliorates myocardial remodeling and function (Ji et al.,
2017). The present data demonstrate that this molecule is able to
modulate cell metabolism and to promote the activation of genes
involved in the control of inflammation and of lipid consumption
to produce energy.
MATERIALS AND METHODS
Solid Lipid Nanocarriers (SLN)–Myriocin
Preparation
Solid lipid nanocarriers (SLN) loaded with myriocin (SLN/myr,
1 mM) were prepared as previously described (Caretti et al.,
2014) by Nanovector S.r.l., Italy, and stored at −80◦C until use.
SLN/myr stock was diluted 1:4 in 0.9% NaCl sterile solution.
Ethics Statement
Animal studies were conducted in accordance with the Guide
for the Care and Use of Laboratory Animals (National Institutes
of Health, Publication No. 85–23, revised 1996) and with the
ARRIVE guidelines and adhered strictly to the Italian Ministry of
Health guidelines for the use and care of experimental animals.
Authorization number 361/2017-PR by the Italian Institute of
Health (Istituto Superiore della Sanità).
Left Anterior Descending (LAD) Coronary
Ligature
We used male C57BL/6N mice (Charles River Laboratories
Italia, Italy), 8–10 weeks old. Animals were anesthetized by
intraperitoneal injection of Medetomidine, 0.5 mg/Kg (Orion
Pharma S.r.l.) and Ketamine, 100 mg/Kg (Merial), diluted
in saline solution. When completely unconscious, mice were
ventilated through an endotracheal tube at 200µL of tidal volume
with a respiration rate of 110 breaths/min. Mice were placed on
a heating pad at 37◦C to maintain a constant body temperature
and their chests were opened by thoracotomy between the second
and the third rib to expose the left ventricle. Once identified
and located the LAD coronary, a 7–0 silk suture was passed
under the coronary vessel, 2 mm below the tip of the left auricle.
Then, the suture was tied with two knots over a 5 mm long
piece of polyethylene tubing to simulate ischemia. To confirm the
occlusion of the LAD a paler color in the anterior wall of the LV
appeared. After 30 min of ischemia, the tubing was removed to
simulate the reperfusion phase (Reforgiato et al., 2016). Groups
ranged from five to seven animals each. In the treated group,
mice were intra-ventricularly injected, right after the beginning
of reperfusion, with 20 µL of SLN/myr, while empty SLN was
used in the control group. Mice belonging to the sham group
were subjected to the same surgical procedure, with the exception
of LAD ligation. The silk suture was left in loco for the staining
procedure. Animals were reawakened by sub-cutaneous injection
of Atipamezole, 5 mg/kg (Orion Pharma S.r.l), and followed for
24 h or 96 h. A sub-cutaneous dose of buprenorphine solution,
0.05 mg/kg (Dechra Pharmaceuticals) was injected immediately
after the surgery and, when necessary, every 8–12 h.
Double-Staining and Quantitative Image
Analysis of Heart Sections
Double staining was performed as previously described
(Reforgiato et al., 2016) to discriminate surviving cells within
the area-at-risk from the dead cells of the infarct area. Briefly,
at the end of reperfusion, the LAD coronary was re-occluded
by tightening the knot around the vessel and 100 µl of 4%
(w/v) Evans blue solution was injected into the apex of the
heart to identify the ischemic area by dye exclusion. Then,
each heart was weighted and cut into 1 mm thick slices, which
were incubated in 1% triphenyl tetrazolium chloride (TTC)
(Sigma-Aldrich, United States) in sodium phosphate buffer
for 5 min to counterstain surviving cells in the area at risk.
The extent of stained and unstained areas was calculated for
each slice from digital images using ImageJ software. The area
at-risk was expressed as the percentage of total area (the entire
surface of each section) whereas the infarct area was expressed
as the percentage of the area-at-risk. Percentages were calculated
as the mean of all section of one heart. When this imaging
procedure was concluded, samples were processed for RNA and
lipids extraction.
Hypertrophy Determination
After 96 h from the LAD occlusion or sham operation, the
anesthetized animals and the collected hearts were weighed.
Heart weight to body weight ratio (HW/BW; mg/g), a common
and simple indicator of cardiac hypertrophy (Chiu et al.,
2001; Sugden et al., 2008; Del Olmo-Turrubiarte et al.,
2015) was calculated.
Ceramide Quantitation
The at-risk and infarcted areas and tissue samples collected
from sham animals were separated by dissection, weighed and
homogenized as previously described (Caretti et al., 2014).
The content of dihydroceramide and ceramide species was
measured by liquid chromatography-mass spectrometry (LC-
MS/MS) following the previously published method (Reforgiato
et al., 2016). Sphingolipids species content was normalized to
tissue weight, expressed in grams.
qRT-PCR
Total RNA was isolated from both the myocardial at-risk area
and tissue samples collected from sham animals, according to
the manufacturer’s instructions (Promega). 1 µg of purified
RNA was reverse transcribed with the iScriptTM cDNA synthesis
kit (Bio-Rad), and the obtained cDNA was stored at −20◦C.
The amplification of target genes was performed using the
GoTaq qPCR Master Mix (Promega) and ROX as reference
dye. Amplified genes included: α-myosin heavy chain (MYH6),
β-myosin heavy chain (MYH7), for the hypertrophic analysis;
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PGC-1α (PPARGC1A), PPAR-α (PPARA), PPAR-γ (PPARG),
PPAR-β/δ (PPARD) and TFEB (TFEB) for the analysis of
transcriptional factors; P62 (SQSTM1) for the analysis of TFEB
activity; VLDLR (VLDLR), FATP1 (SLC27A1), h-FABP (FABP3),
CD36 (CD36), CPT-1a (CPT1A), CPT-1b (CPT1B), UCP3
(UCP3) for the study of FA transporters; MCAD (ACADM),
LCAD (ACADL), HSL (LIPE) for the evaluation of the FA
metabolism enzymes; PLIN2 (PLIN2), PLIN4 (PLIN4), PLIN5
(PLIN5) for the analysis of the perilipins involvement in I/R
injury. Relative mRNA expression of target genes was normalized
to the endogenous RPLI control gene and represented as fold
change versus control, calculated by the comparative CT method
(11CT Method). All the primer sequences are reported in the
Supplementary Table S1.
Ex vivo Enzymatic Activities
Left ventricular samples were used for mitochondria extraction
from tissue homogenates and measurement of oxidative
phosphorylation (OXPHOS) (Buondonno et al., 2016) and
ATP concentration were performed as previously described
(Campia et al., 2009). The rate of reduction of cytochrome
c, an index of the electron transport between Complex I–III
and OXPHOS rate, was measured spectrophotometrically on
10 µL of non-sonicated mitochondrial samples. The results
were expressed as nmoles cyt c reduced/min/mg mitochondrial
proteins. FAO analysis was performed as previously reported
(Capello et al., 2016), by radiolabeling for 2 h tissue homogenates
with 2 µCi [1−14C] palmitic acid (3.3 mCi/mmol, PerkinElmer,
Waltham, MA, United States) and measuring the labeled
acid soluble metabolites (ASM), as products of FAO, by
liquid scintillation. The results were expressed as pmoles 14C-
ASM/h/mg proteins.
Statistical Analysis
For the animal experiments, five to seven mice were used for each
group; all the further anatomical and biochemical analyses were
performed on the tissues collected from these groups. Graphs
were elaborated using the GraphPad Prism 7 software. Data are
expressed as mean± SD calculated from experimental replicates.
Data significance was evaluated by unpaired Student’s T-test
(significant when p-value< 0.05).
RESULTS
Single Intra-Myocardial Injection of
SLN/myr Lowers Myocardial Ceramide
Content, Reducing Infarct Size and
Hypertrophy
We performed intra-ventricular injection of SLN/myr at the
start of reperfusion (post-conditioning) after left ventricle
induced ischemia (LAD, 30 min occlusion). We observed
that the SLN/myr post-conditioning significantly decreased
the percentage of infarct area (21.87% ± 0.78 at 24 h and
26.88% ± 2.23 at 96 h), as compared to the untreated
animals (respectively, 35.85% ± 2.44 and 37.05% ± 2.97),
up to 96 h after I/R (Figure 1A). The size of the area-at-
risk was not affected by the treatment (Figure 1B), indicating
a consistent LAD procedure (Reforgiato et al., 2016). Our
previous study suggested that ceramide increase occurred
at reperfusion and drove inflammatory responses, enhancing
myocardial damage (Reforgiato et al., 2016). Therefore, we
evaluated the effect of Myriocin in the 24 h following reperfusion,
with the aim of investigating if the initial accumulation of
this lipid can be responsible for the following remodeling
events, specifically in the at-risk area, which is subjected to
further damage in the post-infarct phase, and which is the
target of post-conditioning. By means of LC-MS/MS analysis,
we observed that the level of ceramide was increased by
I/R not only in the infarct area, but also in the at-risk
area, as compared to sham, and it was reduced by SLN/myr
treatment, within the at-risk area (Figure 1C). Since Myriocin
inhibits the de novo synthesis of ceramide, we also measured
the content of its precursor dihydroceramide (Figure 1D).
As expected, dihydroceramide accumulated after I/R, and it
was significantly reduced by SLN/myr treatment, mirroring
ceramide. The amount of the single dihydroceramide and
ceramide chains is reported in Supplementary Figures S1, S2,
respectively (Supplementary Figures S1, S2). To evaluate the
effects of ceramide on pathological remodeling, we analyzed
the expression of cardiac specific myosin heavy chains. We
observed that Myriocin post-conditioning reverted the infarct-
induced altered expression of the myosin chains. In particular,
the I/R-induced increased expression of the fetal β-MHC isoform
was markedly reduced by SLN/myr treatment (Figure 1E).
On the other hand, while I/R injury lowered the expression
of the adult α-MHC gene at 24 h in both myriocin treated
and non-treated mice, SNL/myr post-conditioning significantly
increased the expression of α-MHC at 96 h post-surgery, as
compared to untreated animals (Figure 1F). Furthermore, we
investigated if the reduction of infarct size could correlate with
a reduced development of hypertrophy, another hallmark of
adverse remodeling. We measured a significant increment in
the HW/BW ratio, representing the extent of left ventricular
hypertrophy, in the I/R group, as compared to sham. SLN/myr
treatment inhibited this effect (Figure 1G).
Myriocin Drives a Transcriptional
Program Controlling Energy Metabolism
In view of their key role in controlling oxidative stress
response and energy metabolism, we investigated the activation
of the transcription factor TFEB and of the PPARs nuclear
factors family. The expression of TFEB is down-regulated in
the immediate post-I/R, but it is significantly enhanced by
SLN/myr treatment, as compared to untreated mice (Figure 2A).
TFEB transcriptional target SQSTM1 is increasingly up-
regulated by Myriocin treatment as well (Figure 2B). In line
with literature data, PPARs transcription is down-regulated
by I/R stress in myocardium (Abdelrahman et al., 2005;
Morrison and Li, 2011). On the contrary, the expression of
the key lipid homeostasis regulator PPAR-γ is significantly
increased by SLN/myr, as compared to untreated animals,
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FIGURE 1 | Analysis of SLN/myr treatment effects on infarct areas, sphingolipid content and hypertrophy. (A) analysis of the infarct area (expressed as percentage
on at-risk area, on the left) and (B) of the area at-risk (expressed as percentage on total tissue, on the right) in infarcted myocardium, 24 h and 96 h after surgery.
(C) LCMS measurement of ceramides and (D) dihydroceramides species in infarct and at-risk area, 24 h and 96 h after surgery. qRT-PCR analysis of (E) β-myosin
heavy chain (MYH7) and (F) α-myosin heavy chain (MYH6), 24 h and 96 h after surgery, expressed as relative quantity versus sham group. (G) measurement of
myocardial hypertrophy, 96 h after surgery, calculated as ratio between heart weight on body weight. All data are expressed as mean ± SD. Statistical significance
refers to I/R and SLN/myr treated I/R groups as compared to sham animals. The comparison between I/R and SLN/myr treated I/R groups is indicated by the
connecting line (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001). Sham animals: gray bar; I/R group: white bar; SLN/myr treated I/R group: black bar.
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FIGURE 2 | Quantification of TFEB expression levels and gene transcription measurement of PPARs, their activators, and the autophagy-related gene Sqstm1.
Quantification of panel (A) TFEB RNA levels, along with TFEB target gene transcription SQSTM1 (B). Quantification of PPAR transcription factor family [PPARG (C),
PPARA (D), PPARD (E)] and of the PPARGC1A co-activator (F). Target gene expressions are measured by qRT-PCR analysis and are expressed as relative quantity
on sham group. All measurements are referred to 24 and 96 h after surgery. All data are expressed as mean ± SD. Statistical significance refers to I/R and SLN/myr
treated I/R groups as compared to sham animals. The comparison between I/R and SLN/myr treated I/R groups is indicated by the connecting line (∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001). Sham animals: gray bar; I/R group: white bar; SLN/myr treated I/R group: black bar.
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since early time of treatment (Figure 2C). PPAR-α is up-
regulated as well, reaching significant increase between Myriocin-
treated or untreated mice, at 96 h after post-conditioning
(Figure 2D). PPAR-δ expression is only mildly reduced by I/R,
but significantly up-regulated by SLN/myr post-conditioning
at 96 h (Figure 2E). The expression of PPARs co-activator
PGC-1α was investigated as well. PGC-1α transcription was
progressively down-regulated after LAD occlusion. As expected,
SLN/myr counteracted this inhibition reaching a statistical
significance in the increase at 96 h as compared to untreated
animals (Figure 2F).
Ceramide Synthesis Inhibition Modulates
the Expression of Genes Involved in Lipid
Transport and Mobilization
We investigated the expression pattern of FA entry mediators
located on the plasma membrane and of their cytosolic
transporters: the lipoproteins receptor Vldlr, the lipid
transporters Fatp1 (SLC27A1) mediating mainly the uptake
of long-chain FA, the CD36 FA translocase, and the cardiac
cytosolic transporter FA binding protein (FABP3). All these
proteins’ expression was affected by I/R and significantly
down-regulated during the following 96 h. SLN/myr treatment
recovered the expression of lipid entry/transport regulators
and this effect became significant at 96 h post-I/R injury,
as compared to Myriocin-untreated mice (Figures 3A–D).
Myocardium organizes fat storage by intracellular droplets
that take part to metabolism homeostasis. Therefore, we then
evaluated the expression of enzymes involved in the mobilization
of lipid storage. The hormone-sensitive lipase (HSL) is a
cellular lipase interacting with perilipins, which catalyzes the
hydrolysis of stored triglycerides in lipid droplets to free FAs
(Deng et al., 2006). Interestingly, LIPE gene transcription was
significantly increased in SLN/myr treated animals at 96 h
post-surgery, as compared to untreated ones (Figure 3E).
In parallel, we investigated the effects of SLN/myr on the
expression of perilipin genes, belonging to the PAT family of
cytoplasmic lipid droplet binding proteins. After I/R injury, all
perilipins were up-regulated by myriocin post-conditioning.
In particular, PLIN2 expression was significantly increased at
24 h, whereas PLIN4 expression significantly increased after 96 h
post-surgery (Figures 3F–H).
Ceramide Synthesis Inhibition Stimulates
FA Oxidation and Energy Production
In order to understand the fate of lipid mobilization, we
investigated the lipid shuttle system associated with the outer
mitochondrial membrane, mediated by Cpt1a and Cpt1b
proteins, which transport activated FA within the mitochondrial
matrix. I/R injury induced a significant reduction of the
expression of these transporters at 96 h after surgery in untreated
mice. However, SLN/myr post-conditioning counteracted CPT1a
and CPT1b expression decrease, inducing a significant increase
at 96 h compared to untreated mice (Figures 4A,B). Moreover,
we analyzed the expression of the mitochondrial carrier UCP3,
which is associated with the survival response to oxidative
stress and with FA mitochondrial transport. Results showed
a significant down-regulation of UCP3 during the remodeling
phase after I/R (96 h), as compared to controls, supporting
observations also reported by other authors (Song et al.,
2016). On the contrary, SLN/myr post-conditioning significantly
enhanced UCP3 expression, as compared to myriocin untreated
mice (Figure 4C).
In order to assess whether fat entry and mobilization was
finalized at oxidation and energy production, we evaluated the
post-conditioning induced transcriptional response of enzymes
involved in mitochondrial FAO. MCAD and LCAD, the
mitochondrial dehydrogenases that are primarily responsible for
β-oxidation of medium and long chains Fas, respectively, were
down-regulated by I/R injury, at both time points considered,
as compared to sham. Remarkably, Myriocin post-conditioning
partially restored, at 96 h, both dehydrogenases expression in
treated mice, to levels significantly higher than untreated animals
(Figures 4D,E). To support these findings, we measured the
FA β-oxidation ex vivo, within the at-risk area of SLN/myr
treated or untreated myocardium. Interestingly, we observed a
significant increase in β-oxidation activity in Myriocin treated
animals, as compared to untreated mice (Figure 4F). Since FA
oxidation is aimed at energy production, we also evaluated the
activity of the mitochondria electrons chain transfer (ETC) and
the ATP production. As expected, we observed a significant
increase of ETC upon SLN/myr post-conditioning after I/R
(Figure 4G), whereas ATP production showed an increasing
trend in Myriocin treated animals, as compared to untreated
ones (Figure 4H).
DISCUSSION
We here extended our previous study on Myriocin post-
conditioning (Reforgiato et al., 2016) to the remodeling phase
occurring in the first days after myocardial I/R. The presented
data suggest that modulation of FA oxidation, exerted by
Myriocin (SLN/myr), reduces cardiac I/R damage. First, we
demonstrated that intraventricular injection of SLN/myr at the
beginning of reperfusion significantly affects infarct size up to
4 days from LAD occlusion (Figure 1A). Myriocin inhibits the
biosynthesis of sphingolipids, which is enhanced in inflammatory
conditions (Caretti et al., 2014; Signorelli et al., 2016) and,
specifically, in the myocardium under I/R (Reforgiato et al.,
2016). Tissue content of both ceramide and its precursor
dihydroceramide was reduced in the at-risk area of SLN/myr-
treated myocardium (Figures 1C,D), indicating that ceramide
accumulation after I/R was effectively deriving from its de novo
synthesis and that this mechanism acquired a pathological role.
Moreover, Myriocin post-conditioning restrained the extent of
the I/R damage, thus preventing the development of cardiac
hypertrophy (Figure 1E) and counteracting cardiac myosin heavy
chain expression switch (α- and β-MHC), which characterizes
adverse remodeling (Figures 1F,G). The metabolism drift,
which is associated with reduced lipid consumption for energy
production and caused by I/R injury, is sustained by a
transcriptional program. Indeed, the expression of genes involved
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FIGURE 3 | Quantification of the expression levels of lipid transporters and proteins involved in their mobilization. qRT-PCR analysis of the plasma membrane
transporters: VLDLR (A), SLCL27A1 (B), CD36 (C), FABP3 (D). qRT-PCR analysis of the FA mobilization enzymes and of the PAT family members: LIPE (E), PLIN2
(F), PLIN4 (G) and PLIN5 (H). All data are reported as relative quantity on sham group and are referred to 24 and 96 h after surgery. All data are expressed as
mean ± SD. Statistical significance refers to I/R and SLN/myr treated I/R groups as compared to sham animals. The comparison between I/R and SLN/myr treated
I/R groups is indicated by the connecting line (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001). Sham animals: gray bar; I/R group: white bar; SLN/myr
treated I/R group: black bar.
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FIGURE 4 | Quantification of mitochondria FA transporters expression, FA oxidation and energy production. qRT-PCR analysis of the mitochondria transporters
CPT1a (A) and CPT1b (B). qRT-PCR expression analysis of enzymes involved in mitochondrial FAO: UCP3 (C), MCAD (D) and LCAD (E). Target gene expressions
are measured by qRT-PCR analysis and are expressed as relative quantity on sham group. All measurements are referred to 24 and 96 h after surgery. Analysis of
β-oxidation and energy production: β-ox (F), ETC (G) and ATP content (H). These measurements are referred to 24 h after surgery. All data are expressed as
mean ± SD. Statistical significance refers to I/R and SLN/myr treated I/R groups as compared to sham animals. The comparison between I/R and SLN/myr treated
I/R groups is indicated by the connecting line (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001). Sham animals: gray bar; I/R group: white bar; SLN/myr
treated I/R group: black bar.
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in FA transport and oxidation was already shown to be down-
regulated in I/R injury and HF models (Stanley et al., 2005;
Amorim et al., 2010). Consequent accumulation of cardiac
fat induces lipotoxicity (Schulze, 2009). Lipid mobilization to
sustain energy production under stress conditions is a process
orchestrated by the transcriptional factor TFEB that promotes
lysosomal fat degradation (lipophagy) and the re-activation of
their mitochondrial oxidation and ATP production (Settembre
and Ballabio, 2014). TFEB is known to activate a set of
genes involved in lipid mobilization and oxidation, mostly
by the induction of the transcriptional activities of PPARs
and their co-activator PGC-1α (Settembre and Ballabio, 2014).
Of note, TFEB signaling is suppressed in mouse hearts with
advanced cardiac proteinopathy, and it plays a critical role in
the cytoprotection in hypoxia/re-oxygenation injury in cultured
cardiac myocytes (Pan et al., 2017). Our data show that SLN/myr
post-conditioning induces a rapid increase in TFEB mRNA
expression (Figure 2A) within the at-risk area, as compared to
untreated mice. A TFEB key target is p62-sequestosome, a key
component of autophagy vesicles that connect TFEB activation
to lipophagy, in support of mitochondrial β-oxidation of FA.
Moreover, p62-sequestosome loss is also associated with diabetes
and obesity (Angelini et al., 2016). As expected, we found an
increased transcription of p62-sequestosome in 96 h SLN/myr-
treated myocardial at-risk area (Figure 2B). p62-sequestosome
is known to sequester Keap 1 and to release active Nrf2,
which potently induce an anti-oxidant response (Jain et al.,
2015). We already demonstrated that Nrf2 was induced by
SLN/myr post-conditioning in myocardial I/R (Reforgiato et al.,
2016) and that Myriocin activated this transcriptional factor to
counteract inflammation (Caretti et al., 2016). The activation
of PPARs, particularly of PPAR-γ, has been lately proposed as
a therapeutic target to limit the extent of myocardial damage
after I/R (Abdelrahman et al., 2005; Morrison and Li, 2011).
SLN/myr protection from I/R damage was also sustained by
the increased transcription of all three isoforms of PPARs
and of their co-activator PGC1α (Figures 2C–F). Thus, these
results supported the hypothesis that Myriocin enhances lipid
catabolism and anti-oxidant response via TFEB and PPARs
integrated transcriptional activities, in order to recover cardiac
metabolism control in the post-infarct remodeling phase. To
confirm this hypothesis, we investigated the expression of
specific genes downstream to these transcriptional factors.
PPAR-γ was reported to up-regulate the expression of VLDLR
(Yagyu et al., 2002; Tao et al., 2010), and such expression
is in turn related to the cellular lipid catabolism rate (Yagyu
et al., 2002; Tao et al., 2010). PPARs-induced transcription is
associated with the activities of key lipid mobilizing enzymes.
Specifically, PPAR-γ was reported to induce LIPE Hormone-
Sensitive Lipase type E (HSL), the one lipase showing a broader
substrates affinity (Deng et al., 2006; de la Rosa Rodriguez
and Kersten, 2017). PPARs (mostly α and γ) are reported
to promote the expression of genes involved in FA transport
(FATP, FAT/CD36, FABP), FA mitochondrial import (CPT-
I) and mitochondrial β-oxidation (MCAD, LCAD, VLCAD)
(Barger and Kelly, 2000; Nakamura et al., 2014). Among PPARs
target genes, there are also the UCP mitochondrial proteins,
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FIGURE 5 | Schematic representation of the molecular mechanism
responsible for the Myriocin-induced up-regulation of lipid catabolism and
mitochondrial oxidative processes.
which mediate FA import and reduce proton gradient and ROS
formation (Villarroya et al., 2007). UCP3 is down-regulated
in myocardial I/R injury and PPAR-γ activation restores its
expression, inducing cardioprotection (Song et al., 2016). Along
this line, Myriocin post-conditioning induced an increase in
the expression of all the above-reported genes implicated in FA
uptake and their mitochondrial transport, demonstrating that the
transcriptional program, initiated at 24 h by TFEB and PPAR-
γ effectively acted to potentiate cell lipid metabolism in the
following hours (Figures 3A–G).
Lipid droplets are considered dynamic stores of metabolic
fuel, sustaining cellular FA oxidation and representing a source
of inflammatory mediators and gene transcription regulators
(Cabodevilla et al., 2013). Lipid excess, especially triglycerides,
are stored in lipid droplets. Little lipid droplets accrual normally
occurs in the myocardium (Goldberg et al., 2012). Nonetheless,
their accumulation associates with many types of stress, including
fasting (Suzuki et al., 2001, 2002; Cabodevilla et al., 2013). In
isolated cardiomyocytes exposed to anoxia and re-oxygenation,
cell death was attenuated in those containing lipid droplets,
indicating their cardioprotective effects (Lei et al., 2013). The lipid
droplet associated perilipins, PLIN2, 3, 4 and 5, are all expressed
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in the heart (Paul et al., 2008). PLIN5 is known to be up-regulated
by PPAR-α agonists, and it controls lipid homeostasis (Chen
et al., 2013) in the myocardium (Paul et al., 2008). Moreover,
it was demonstrated to be cardioprotective during myocardial
ischemia (Drevinge et al., 2016), and its deficiency significantly
increased oxidative stress (Kuramoto et al., 2012; Lei et al.,
2013). Of note, patients carrying a minor allele of PLIN5 are at
higher risk of cardiovascular morbidity after myocardial ischemic
events and characterized by decreased survival (Drevinge et al.,
2016). Remarkably, SLN/myr post-conditioning resulted in the
up-regulation of all three PLIN isoforms, as compared to
untreated animals.
Most importantly, SLN/myr post-conditioning effectively
increased FA mitochondria β-oxidation, thus enhancing electron
transport and ATP production (Figures 4C–D). These results
support that the significant induction of lipid-catabolism, as
well as the activation of mitochondrial oxidative processes
mediated by Myriocin, could be central in the therapeutic activity
of the molecule.
CONCLUSION
The data presented unveiled the molecular mechanisms of
Myriocin effects in I/R injury response, which go beyond
the simple reduction of ceramide synthesis and extended
our previous findings, revealing that Myriocin beneficial
effects are not limited to the initial phase of I/R injury, but
they can counteract early cardiac remodeling. Along this
line, Myriocin post-conditioning activates a transcriptional
program that drives the energy metabolism during the
I/R injury-induced cardiac remodeling phase. In particular,
results support that the inhibition of sphingolipid synthesis
induced by the molecule causes a starvation-like signal, which
eventually modulates the master regulators of lipid consumption,
mitochondria formation, and anti-oxidant activities (Figure 5).
Indeed, the adverse outcome of myocardial I/R associates
with metabolism derangement, lipid accumulation, reduced
energy production and impaired contractility. Thus, the
capacity of Myriocin to regulate both cardiac inflammation
and metabolism after I/R injury support the hypothesis
of its use as a possible post-conditioning therapeutic
(patent number: US 9925160 B1).
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FIGURE S1 | LC-MS/MS quantitation of dihydroceramide species in the at-risk
area. Dihydroceramide species C-16:0 (∗∗∗p < 0.001) is increased in I/R sample.
Dihydroceramide species C-24:0 (∗p < 0.05) is increased in I/R sample,
meanwhile is reduced by SLN/myr treatment vs. I/R group (∗∗p < 0.01). All data
are referred to 24 h after surgery. Data are expressed as mean ± SD. Sham
animals: gray bar; I/R group: white bar; SLN/myr treated I/R group: black bar.
FIGURE S2 | LC-MS/MS measurement of ceramide species in the at-risk area.
Ceramide species C-16:0 (∗p < 0.05) and C-20:0 (∗∗∗p < 0.001) are increased in
I/R sample, meanwhile C-16:0 and C-18:1 are reduced by SLN/myr treatment vs.
I/R group (∗p < 0.05). All data are referred to 24 h after surgery. Data are
expressed as mean ± SD. Sham animals: gray bar; I/R group: white bar; SLN/myr
treated I/R group: black bar.
TABLE S1 | Murine primers set to qRT-PCR. Table shows the primers used to
perform quantitative real time PCR of target genes.
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